111 (8110) AI Stock Analysis

1 Followers

111

(Frankfurt:8110)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Asset-Light Platform StrategyThe shift away from underperforming subsidiaries toward an asset-light platform may improve business quality and scalability over time. A leaner model can reduce operational complexity, focus resources on higher-value digital services, and support more durable marketplace economics if execution continues.

Negative Factors

Contracting RevenueThe sharp quarterly revenue decline and lower trailing revenue indicate that the current business transition is reducing scale. Although divestitures were deliberate, sustained contraction can weaken market reach and make it harder for fixed platform, technology, and corporate costs to be absorbed.

111 (8110) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 25.04M
Dividend Yield: ―
Average Volume (3M): 2,383
Price to Earnings (P/E): -1.6
Beta (1Y): 0.99
Revenue Growth: -29.17%
EPS Growth: -35.63%
Country: Germany
Employees: 1,063
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Distribution

111 Business Overview & Revenue Model

Company Description

Based in Shanghai, People's Republic of China, 111, Inc. (established in 2010 and formerly known as New Peak Group until April 2018) is a prominent entity in the Chinese healthcare sector, operating a comprehensive online-to-offline (O2O) ecosystem....

111 Earnings Call Summary

Earnings Call Date:Mar 20, 2025(Q4-2024)|% Change Since:-70.70%|Next Earnings Date:Jun 04, 2026

Earnings Call SentimentPositive

The earnings call demonstrates significant achievements in operational profitability and cost reduction despite challenging macroeconomic conditions and regulatory changes. The company's advancements in technology and supply chain expansion position it well for future growth, though market and competitive pressures remain.

Positive Updates

First Ever Operational Profitability

111 achieved its first ever operational profitability and positive operating cash flow in 2024, marking a significant milestone in the company's history.

Negative Updates

Macroeconomic Challenges in China

Economic uncertainties and healthcare reforms in China have led to cautious consumer behavior, affecting retail sales and healthcare expenditure growth.

Company Guidance

During the conference call held on March 20, 2025, the management of 111 provided insights into their fiscal year 2024 performance and future outlook. Despite macroeconomic challenges and healthcare reforms impacting the industry, 111 achieved its first-ever operational profitability and positive operating cash flow. The company reduced operating expenses by 31% year-over-year, bringing them down to 5.7% of revenues. Key financial highlights included a yearly profit from operations of RMB2.1 million, a turnaround from a RMB350.1 million operational loss in 2023, and a non-GAAP income from operations of RMB22.3 million. The company also highlighted advancements in technology and supply chain infrastructure, such as their decentralized inventory network and AI-driven demand forecasting, which significantly improved operational efficiency. Looking ahead, 111 plans to leverage AI and digital transformation to enhance customer engagement and operational efficiency, aiming to capitalize on China's evolving healthcare market and structural trends like the aging population and healthcare transparency reforms.

111 Risk Analysis

111 disclosed 83 risk factors in its most recent earnings report. 111 reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks

1.If the PCAOB is prevented from fully evaluating audits and quality control procedures of our auditor, investors may be deprived of the benefits of such PCAOB inspections.Q4, 2023

2.It may be difficult for regulators to conduct cross-border investigation.Q4, 2023

3.An outbreak of disease or similar public health threat, or fear of such an event, could have a material adverse impact on our business, operating results and financial conditionQ4, 2023

111 Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:8110 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RMTI	52Neutral	$28.54M	-5.01	-16.04%	―	-3.96%	7.97%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ELUT	51Neutral	$40.75M	0.71	267.71%	―	-52.81%	7.54%
NEUP	48Neutral	$14.66M	-0.35	-77.03%	―	―	―
RNTX	43Neutral	$52.28M	-0.30	-234.45%	―	―	36.23%
DYAI	40Underperform	$15.54M	-1.64	-2918.10%	―	-8.05%	-14.12%

* Healthcare Sector Average

Performance Comparison

DE:8110 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:8110	111, Inc.	2.52	-0.82	-24.55%
RMTI	Rockwell Medical	7.38	-1.28	-14.74%
DYAI	Dyadic International Inc.	0.35	-0.54	-60.67%
RNTX	Rein Therapeutics, Inc	0.56	-0.66	-54.10%
ELUT	Elutia Inc.	0.88	0.15	20.27%
NEUP	Neuphoria Therapeutics Inc.	2.58	-2.12	-45.11%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

111 AI Stock Analysis